Logo

Immutep Partners with Merck to Conduct P-III Study of Eftilagimod Alfa (Efti) with Keytruda for Treating NSCLC

Share this
Immutep

Immutep Partners with Merck to Conduct P-III Study of Eftilagimod Alfa (Efti) with Keytruda for Treating NSCLC

Shots:

  • Immutep & Merck have signed a clinical trial collaboration & supply agreement for P-III (TACTI-004) study of eftilagimod alfa (efti) plus Keytruda & CT to treat NSCLC
  • The P-III (TACTI-004) trial will assess efti + Keytruda & CT vs PBO + Keytruda & CT as a 1L treatment of metastatic NSCLC (incl. both squamous & non-squamous subtypes) patients (n=750), irrespective of PD-L1 expression
  • As per the agreement, Immutep will be responsible for the P-III trial with Merck providing Keytruda for the same. Both companies will keep commercial rights of their compounds & can carry out other clinical evaluations independently or together in any therapeutic area; can look for marketing authorization in a relevant indication
     

Ref: Immutep Image: Immutep

Related News:- Immutep Enters into a Clinical Trial Collaboration with Merck KGaA and Pfizer to Evaluate Eftilagimod Alpha (Efti) for Urothelial Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions